Ann Mongan, director of translational research at BMS, outlines how biomarkers hold pivotal roles in clinical trials.

Historically, pregnant women have been excluded from clinical trials due to safety concerns, but the WHO is pushing for change.

CatalYm has commenced dosing the first subject in its Phase II/III VINCIT trial, assessing the safety and efficacy of its lead anti-GDF-15 antibody, visugromab, in cancer-associated cachexia.

Epitopea has secured approval from the MHRA and the REC in the UK for its OVACT CTA targeting advanced high-grade serous ovarian cancer.

Approval for Xeltis’s aXess device was based on pivotal trial data that demonstrated 79% secondary patency and a patency-related reintervention rate of 1.3 per patient year.

Roche has reported new findings from the Phase III METEOROID trial of Enspryng in adults and adolescents with MOGAD.

At AAN 2026, Argenx announced positive results from the Phase III, double-blind, placebo-controlled, ADAPT SERON study of Vyvgart.

At AAN 2026, Cabaletta Bio announced positive results from the Phase I/II open-label, RESET-MG study of rese-cel in patients with gMG.

Agenus has reported results from a Phase II trial, evaluating the combination of BOT, BAL, and agenT-797 alongside ramucirumab and paclitaxel, in advanced PD-1 refractory gastroesophageal ...

AstraZeneca’s tozorakimab has shown benefit in a third Phase III trial in chronic obstructive pulmonary disorder (COPD).

Acerand Therapeutics has reported updated findings from its first-in-human Phase I/II study of ACE-106 to treat advanced solid tumours.

Rivus Pharmaceuticals has dosed the first patients in the AMPLIFY Phase II clinical trial evaluating HU6, an investigational oral therapy for MASH.